Literature DB >> 19419335

Ocular pathologic response elicited by Chlamydia organisms and the predictive value of quantitative modeling.

David P Wilson1, Anne K Bowlin, Patrik M Bavoil, Roger G Rank.   

Abstract

BACKGROUND: Chlamydia organisms are a significant cause of ocular and genital tract disease worldwide. Acute inflammatory responses are largely responsible for pathologic changes.
METHODS: Guinea pigs were inoculated in the conjunctiva with various infectious doses of Chlamydia caviae. We developed a predictive model and thresholds of the ocular pathologic response, on the basis of measurements of the pathologic response and chlamydial inclusion-forming unit (ifu) loads, using statistical and mathematical techniques. We validated the predictions by modifying the pathologic response with the use of a lytic chlamydiaphage.
RESULTS: If the area under the inclusion-forming unit curve reaches approximately 4x10(5) "ifu-days," then it is likely that an ocular pathologic response will develop and that a serious pathologic finding can develop quickly. The earlier that a pathologic response arises, the longer it will remain. A 2-log10 reduction in the peak inclusion-forming unit load reduces the chance of any pathologic finding emerging from 81% to 32%, and it reduces the chance of a serious pathologic finding emerging from 33% to 2%. A reduction in the peak chlamydial load also substantially reduces the duration of the pathologic response.
CONCLUSIONS: Our predictive model can be used to evaluate the likely effect of interventions that modify the course of chlamydial infection. It suggests that, to be effective in preventing or mitigating pathologic responses, an intervention is required to change the chlamydial time course before the peak inclusion-forming unit load is reached.

Entities:  

Mesh:

Year:  2009        PMID: 19419335     DOI: 10.1086/599093

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Essential role for neutrophils in pathogenesis and adaptive immunity in Chlamydia caviae ocular infections.

Authors:  H Marie Lacy; Anne K Bowlin; Leah Hennings; Amy M Scurlock; Uma M Nagarajan; Roger G Rank
Journal:  Infect Immun       Date:  2011-03-14       Impact factor: 3.441

2.  Chlamydia trachomatis load in population-based screening and STI-clinics: implications for screening policy.

Authors:  Jeanne A M C Dirks; Petra F G Wolffs; Nicole H T M Dukers-Muijrers; Antoinette A T P Brink; Arjen G C L Speksnijder; Christian J P A Hoebe
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

3.  STI-GMaS: an open-source environment for simulation of sexually-transmitted infections.

Authors:  Martin R Nelson; Kelly J Sutton; Bindi S Brook; Dann G Mallet; Daniel P Simpson; Roger G Rank
Journal:  BMC Syst Biol       Date:  2014-06-12

4.  Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.

Authors:  Aleksandra Inic-Kanada; Marijana Stojanovic; Simone Schlacher; Elisabeth Stein; Sandra Belij-Rammerstorfer; Emilija Marinkovic; Ivana Lukic; Jacqueline Montanaro; Nadine Schuerer; Nora Bintner; Vesna Kovacevic-Jovanovic; Ognjen Krnjaja; Ulrike Beate Mayr; Werner Lubitz; Talin Barisani-Asenbauer
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

5.  Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies.

Authors:  Alexander Badamchi-Zadeh; Paul F McKay; Martin J Holland; Wayne Paes; Andrzej Brzozowski; Charles Lacey; Frank Follmann; John S Tregoning; Robin J Shattock
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

6.  The effect of infectious dose on humoral and cellular immune responses in Chlamydophila caviae primary ocular infection.

Authors:  Ana Filipovic; Ehsan Ghasemian; Aleksandra Inic-Kanada; Ivana Lukic; Elisabeth Stein; Emilija Marinkovic; Radmila Djokic; Dejana Kosanovic; Nadine Schuerer; Hadeel Chalabi; Sandra Belij-Rammerstorfer; Marijana Stojanovic; Talin Barisani-Asenbauer
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.